Madrigal Pharmaceuticals, Inc.
Industry
- Pharmaceuticals
- Biotechnology
Other Names/Subsidiaries
- Principia Associates, Inc.
- Synta Pharmaceuticals Corp.
Latest on Madrigal Pharmaceuticals, Inc.
Thirteen medicines were backed for pan-EU marketing authorizations this week by the European Medicines Agency’s human medicines committee, the CHMP, including Madrigal Pharmaceuticals’ Rezdiffra (resm
The European Medicines Agency’s human medicines committee, the CHMP, is expected to decide this week whether to recommend pan-EU marketing authorization for 12 new medicines, including Madrigal Pharma
Roivant has promised investors it will spend some of its impressive cash stockpile on buying new assets. But midway into the year, no deals have been signed. CEO Matt Gline, in an interview at the com
Following GSK’s $1.2bn acquisition of privately held Boston Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) candidate efimosfermin on 14 May, the industry is wondering what re